Samba Bio has received approval for the drug price of Akugo by the Central Social Insurance Medical Council and has revised its consolidated earnings forecast for the January 2027 period. The drug price is set at 72,716,528 yen, and plans are underway to systematically proceed with clinical trials and medical collaboration frameworks.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"Samba Bio Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4592-20260513-01.pdf","jir_short_summary":"Samba Bio has received approval for the drug price of Akugo by the Central Social Insurance Medical Council and has revised its consolidated earnings forecast for the January 2027 period. The drug price is set at 72,716,528 yen, and plans are underway to systematically proceed with clinical trials and medical collaboration frameworks.","jir_summary":"### Performance Overview\nSamba Bio's drug price for Akugo has been approved by the Central Social Insurance Medical Council, and the final drug price is expected to be set at 72,716,528 yen. Accordingly, the consolidated earnings forecast for the January 2027 period has been revised to project business revenue of 396 million yen, operating income of -5,229 million yen, and net income attributable to owners of parent of -5,133 million yen. The company plans to progress through clinical trials and medical collaborations in stages, and expectations for future developments are rising.\n\n### Outlook and Impact on Shareholders\nWith the approval of the Akugo drug price, efforts will be made to advance clinical trials and the adoption in medical institutions, aiming for phased revenue generation. Although the earnings forecast for the January 2027 period remains cautious, further improvements are anticipated depending on the progress of drug price decisions and clinical development. The company will continue to focus on strengthening clinical trials and healthcare infrastructure to enhance long-term corporate value.","jir_financial_highlights":"Consolidated Earnings Forecast for January 2027 - Business Revenue: 396 million yen (Prior forecast: -)\nConsolidated Earnings Forecast for January 2027 - Operating Income: -5,229 million yen (Prior forecast: -5,625 million yen)\nConsolidated Earnings Forecast for January 2027 - Net Income Attributable to Owners of Parent: -5,133 million yen (Prior forecast: -5,635 million yen)","jir_category":"","jir_hashtags":"#SambaBio, #IRType, #JapaneseStocks","jir_key_figures":"Consolidated Earnings Forecast for January 2027 - Business Revenue: 396 million yen\nConsolidated Earnings Forecast for January 2027 - Operating Income: -5,229 million yen\nConsolidated Earnings Forecast for January 2027 - Net Income Attributable to Owners of Parent: -5,133 million yen","jir_meta_title":"\u3010Samba Bio\u3011 Approval of Akugo Drug Price and Revision of 2027 Earnings Forecast | May 2026","jir_meta_description":"Samba Bio received approval for the Akugo drug price from the Central Social Insurance Medical Council and revised its consolidated earnings forecast for January 2027. Focus is on clinical development and long-term corporate value enhancement.","jir_og_title":"\u3010Samba Bio\u3011 Akugo Drug Price Approval and Earnings Revision | May 2026","jir_og_description":"Samba Bio announces the approval of Akugo's drug price and the revision of its 2027 earnings forecast. Key movements toward clinical development and corporate value growth.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48615","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n